Logo image of CMRX

CHIMERIX INC (CMRX) Stock Fundamental Analysis

NASDAQ:CMRX - Nasdaq - US16934W1062 - Common Stock - Currency: USD

8.54  -0.01 (-0.12%)

After market: 8.54 0 (0%)

Fundamental Rating

4

Taking everything into account, CMRX scores 4 out of 10 in our fundamental rating. CMRX was compared to 561 industry peers in the Biotechnology industry. While CMRX has a great health rating, there are worries on its profitability. While showing a medium growth rate, CMRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CMRX had negative earnings in the past year.
CMRX had a negative operating cash flow in the past year.
CMRX had negative earnings in 4 of the past 5 years.
CMRX had a negative operating cash flow in each of the past 5 years.
CMRX Yearly Net Income VS EBIT VS OCF VS FCFCMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

CMRX has a worse Return On Assets (-60.54%) than 60.49% of its industry peers.
Looking at the Return On Equity, with a value of -72.64%, CMRX is in line with its industry, outperforming 54.67% of the companies in the same industry.
Industry RankSector Rank
ROA -60.54%
ROE -72.64%
ROIC N/A
ROA(3y)-12.49%
ROA(5y)-52.25%
ROE(3y)-16.05%
ROE(5y)-72.22%
ROIC(3y)N/A
ROIC(5y)N/A
CMRX Yearly ROA, ROE, ROICCMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

CMRX has a better Gross Margin (100.00%) than 99.12% of its industry peers.
The Profit Margin and Operating Margin are not available for CMRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMRX Yearly Profit, Operating, Gross MarginsCMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

8

2. Health

2.1 Basic Checks

CMRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CMRX has been increased compared to 1 year ago.
CMRX has more shares outstanding than it did 5 years ago.
CMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CMRX Yearly Shares OutstandingCMRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CMRX Yearly Total Debt VS Total AssetsCMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 10.02 indicates that CMRX is not in any danger for bankruptcy at the moment.
The Altman-Z score of CMRX (10.02) is better than 88.54% of its industry peers.
There is no outstanding debt for CMRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.02
ROIC/WACCN/A
WACC10.2%
CMRX Yearly LT Debt VS Equity VS FCFCMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.70 indicates that CMRX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.70, CMRX is in the better half of the industry, outperforming 61.55% of the companies in the same industry.
A Quick Ratio of 5.70 indicates that CMRX has no problem at all paying its short term obligations.
CMRX has a Quick ratio of 5.70. This is in the better half of the industry: CMRX outperforms 61.90% of its industry peers.
Industry RankSector Rank
Current Ratio 5.7
Quick Ratio 5.7
CMRX Yearly Current Assets VS Current LiabilitesCMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for CMRX have decreased by -7.61% in the last year.
Looking at the last year, CMRX shows a very negative growth in Revenue. The Revenue has decreased by -34.57% in the last year.
CMRX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -55.77% yearly.
EPS 1Y (TTM)-7.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-34.57%
Revenue growth 3Y-52.51%
Revenue growth 5Y-55.77%
Sales Q2Q%1325%

3.2 Future

The Earnings Per Share is expected to grow by 27.51% on average over the next years. This is a very strong growth
Based on estimates for the next years, CMRX will show a very strong growth in Revenue. The Revenue will grow by 381.56% on average per year.
EPS Next Y13.8%
EPS Next 2Y5.53%
EPS Next 3Y24.46%
EPS Next 5Y27.51%
Revenue Next Year2198.64%
Revenue Next 2Y1434.15%
Revenue Next 3Y731.43%
Revenue Next 5Y381.56%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CMRX Yearly Revenue VS EstimatesCMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
CMRX Yearly EPS VS EstimatesCMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CMRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMRX Price Earnings VS Forward Price EarningsCMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMRX Per share dataCMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as CMRX's earnings are expected to grow with 24.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.53%
EPS Next 3Y24.46%

More info and screens

0

5. Dividend

5.1 Amount

CMRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHIMERIX INC

NASDAQ:CMRX (4/17/2025, 8:10:17 PM)

After market: 8.54 0 (0%)

8.54

-0.01 (-0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-21 2025-03-21/bmo
Earnings (Next)05-01 2025-05-01/bmo
Inst Owners54.92%
Inst Owner Change77.96%
Ins Owners7.04%
Ins Owner Change-20.54%
Market Cap801.05M
Analysts76.36
Price Target8.71 (1.99%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.11%
Min EPS beat(2)-7.74%
Max EPS beat(2)5.51%
EPS beat(4)2
Avg EPS beat(4)-2.52%
Min EPS beat(4)-11.63%
Max EPS beat(4)5.51%
EPS beat(8)5
Avg EPS beat(8)1.58%
EPS beat(12)8
Avg EPS beat(12)3.93%
EPS beat(16)8
Avg EPS beat(16)-21.17%
Revenue beat(2)0
Avg Revenue beat(2)-45.75%
Min Revenue beat(2)-66.01%
Max Revenue beat(2)-25.49%
Revenue beat(4)1
Avg Revenue beat(4)-22.29%
Min Revenue beat(4)-100%
Max Revenue beat(4)102.35%
Revenue beat(8)2
Avg Revenue beat(8)-25.17%
Revenue beat(12)5
Avg Revenue beat(12)551.24%
Revenue beat(16)6
Avg Revenue beat(16)413.12%
PT rev (1m)-9.15%
PT rev (3m)1.67%
EPS NQ rev (1m)-1.92%
EPS NQ rev (3m)-3.92%
EPS NY rev (1m)7.04%
EPS NY rev (3m)16.4%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-9.67%
Revenue NY rev (3m)27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3778.55
P/FCF N/A
P/OCF N/A
P/B 6.58
P/tB 6.58
EV/EBITDA N/A
EPS(TTM)-0.99
EYN/A
EPS(NY)-0.85
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0
BVpS1.3
TBVpS1.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -60.54%
ROE -72.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-12.49%
ROA(5y)-52.25%
ROE(3y)-16.05%
ROE(5y)-72.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 305.32%
Cap/Sales 135.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.7
Quick Ratio 5.7
Altman-Z 10.02
F-Score3
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)157.71%
Cap/Depr(5y)122.33%
Cap/Sales(3y)54.35%
Cap/Sales(5y)34.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y13.8%
EPS Next 2Y5.53%
EPS Next 3Y24.46%
EPS Next 5Y27.51%
Revenue 1Y (TTM)-34.57%
Revenue growth 3Y-52.51%
Revenue growth 5Y-55.77%
Sales Q2Q%1325%
Revenue Next Year2198.64%
Revenue Next 2Y1434.15%
Revenue Next 3Y731.43%
Revenue Next 5Y381.56%
EBIT growth 1Y-3.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.52%
OCF growth 3YN/A
OCF growth 5YN/A